EDC in Clinical Trials: An ROI Analysis of Medidata Rave IDC Health Industry Insights
As the volume of information collected in clinical trials continues to grow, data collection and management is becoming a priority for pharmaceutical and biotech companies. Capturing data in a more accurate and timely fashion is a critical component to reducing time to market for potential new drugs. As a result, companies interviewed are aggressively moving from pilot electronic data capture (EDC) implementations to enterprisewide adoption strategies. A survey conducted in 3Q05 demonstrates that the successful completion of pilot EDC implementations will greenlight deployment of EDC in new clinical trials within 12 months. This trend exists across small, midsize, and large contract research organizations (CROs) as well as biotech and pharmaceutical companies. As companies increase their utilization of EDC and proceed further along with EDC adoption, an increasing number of benefits begin to present themselves and become commonplace. This white paper introduces Health Industry Insights’ four-stage EDC Maturity Model as a framework to describe the factors that impact EDC adoption.
